Clinical Trials on Metastatic Intraocular Melanoma

Total 12369 results

Pierre Fabre Medicament

Withdrawn

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Hepatic Impairment | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

Spain, Czechia, Italy
National Cancer Institute (NCI)

Terminated

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Metastatic Cancer | Metastatic Melanoma | Renal Cancer

United States
Herlev Hospital

Completed

Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma

Malignant Melanoma With Metastasis

Denmark
Ohio State University Comprehensive Cancer Center
Bristol-Myers Squibb

Completed

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Lung Metastases | Liver Metastases | Recurrent Melanoma | Stage IV Melanoma | Tumors Metastatic to Brain

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Skin Cancer | Metastatic Melanoma

United States
Vanderbilt-Ingram Cancer Center

Recruiting

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Refractory Melanoma

United States
Brown University
NovoCure Ltd.

Not yet recruiting

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Metastatic Melanoma | Melanoma Brain Metastasis

United States
Apexigen America, Inc.

Terminated

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Melanoma | Cancer | Metastatic Melanoma | Melanoma (Skin) | Unresectable Melanoma | Cancer of Skin

Spain, Poland
Merck Sharp & Dohme LLC

Terminated

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Advanced/Metastatic Melanoma

United States, Australia, Chile, France, Germany, Israel, Italy, Korea, Republic of, Norway, South Africa, Spain
National Cancer Institute (NCI)

Terminated

Drosophila-generated CTL

Metastatic Cutaneous Melanoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Metastatic Cancer | Melanoma (Skin)

United States
Maxim Pharmaceuticals
National Cancer Institute (NCI)

Unknown

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

Metastatic Cancer | Melanoma (Skin)

United States, Canada, Germany, United Kingdom
Iovance Biotherapeutics, Inc.

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Melanoma | Metastatic Melanoma | Unresectable Melanoma

United States, Spain, Australia, France, Netherlands, Italy, Canada, Sweden
BioNTech US Inc.

Recruiting

NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma

Belgium, Netherlands, Spain
Jose Lutzky, MD
Bristol-Myers Squibb; United States Department of Defense

Active, not recruiting

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States
Thomas Jefferson University
Verastem, Inc.

Active, not recruiting

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Central Nervous System

United States
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center; NYU Langone Health

Completed

Study of ADI-PEG 20 in Patients With Advanced Melanoma

Skin Cancer | Metastatic Melanoma | Neoplasm

United States
Scott Pruitt

Completed

Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells

Metastatic Melanoma | Absence of CNS Metastases

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Completed

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

Melanoma (Skin)

United States
Anaveon AG

Recruiting

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Advanced Solid Tumor | Metastatic Melanoma | Melanoma (Skin) | Cutaneous Melanoma | Adult Disease

United States, Spain, Germany, France, Italy
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Cutaneous Melanoma

United States
Mayo Clinic

Active, not recruiting

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)
GlaxoSmithKline; Novartis Pharmaceuticals

Active, not recruiting

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...

United States
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
Memorial Sloan Kettering Cancer Center

Completed

Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors

Metastatic Melanoma

United States
José María Piulats Rodríguez
Instituto de Salud Carlos III

Not yet recruiting

Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma (PULSE-UM)

Uveal Melanoma, Metastatic

Spain
Spectrum Pharmaceuticals, Inc

Completed

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Metastatic Malignant Uveal Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Malignant Solid Neoplasm | Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Bayer

Terminated

A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer

Metastatic Melanoma and Other Solid Tumors

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
University of Kansas Medical Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Recruiting

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
HUYABIO International, LLC.
Bristol-Myers Squibb

Recruiting

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma

Unresectable or Metastatic Melanoma | Progressive Brain Metastasis

Spain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
Karyopharm Therapeutics Inc

Active, not recruiting

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Locally Advanced Unresectable or Metastatic Melanoma

United States
Washington University School of Medicine
Melanoma Research Alliance; Rising Tide Foundation

Not yet recruiting

Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Metastatic Melanoma | Advanced Melanoma

United States
National Cancer Institute (NCI)

Terminated

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cell Cancer

United States
Pfizer

Terminated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Metastatic Pancreatic Adenocarcinoma | BRAF Mutated Melanoma

United States, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
University of California, San Francisco
Xencor, Inc.

Active, not recruiting

XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

Metastatic Melanoma | Advanced Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma | C-KIT Tyrosine Kinase Protein Overexpression | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Gastrointestinal Stromal Tumor | Pathologic Stage IV Cutaneous Melanoma... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

Metastatic Cancer | Melanoma (Skin)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
Pfizer

Completed

Use of 852A in Metastatic Cutaneous Melanoma.

Melanoma | Unresectable Metatstatic Cutaneous Melanoma

Switzerland, Germany, France
Immune Design
Merck Sharp & Dohme LLC

Completed

Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Melanoma - Currently Enrolling | Non-small Cell Lung Cancer - Enrollment Completed | Sarcoma - Enrollment Completed

United States
University of Chicago

Completed

Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer

Melanoma | Sarcoma | Carcinoma | Cancer | Tumor

United States
Leiden University Medical Center

Recruiting

PHP and Immunotherapy in Metastasized UM (CHOPIN)

Uveal Melanoma, Metastatic

Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study (DIET)

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Mayo Clinic

Active, not recruiting

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States

Clinical Trials on Metastatic Intraocular Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations